The development programs of the company include radiotherapeutic, radioimmunotherapeutic and immunotherapeutic products for treatment of various solid cancers. The company has developed proprietary antibodies and holds a license for other antibodies. The antibodies are used as targeting modules of the immune-and radioimmunotherapeutic candidates. These candidate products are in a discovery phase.